Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ICA02
- Development stage
- Preclinical
- Lead developer
- iCamuno Biotherapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular
01
Overview
ICA02 is an allogeneic, "off-the-shelf" cell therapy candidate developed by Aikailiyuan Biotechnology (also known as Icamuno Bio). It consists of mesenchymal stem cells derived from induced pluripotent stem cells (iMSCs) using the company's proprietary iCam-iPSC platform. By utilizing iPSC technology, ICA02 aims to overcome the limitations associated with primary donor-derived MSCs, such as limited expansion capacity, cellular senescence, and significant batch-to-batch variability. The therapy is designed to leverage the natural immunomodulatory and regenerative properties of mesenchymal stem cells to treat a variety of conditions, including inflammatory diseases and degenerative disorders. The use of an iPSC-based platform allows for the large-scale, standardized production of therapeutic cells that can be genetically modified if necessary to enhance their clinical profile.
- Other names
- iPSC-derived Mesenchymal Stem CellsiMSC (Icamuno)
Beyond the preview
Go deeper on ICA02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ICA02.